Literature DB >> 9811467

Mapping of chromosome 3p deletions in human epithelial ovarian tumors.

H Lounis1, A M Mes-Masson, F Dion, W E Bradley, R J Seymour, D Provencher, P N Tonin.   

Abstract

Epithelial ovarian tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of tumor suppressor genes within the deleted regions. We have recently established a primary tissue culture system as a model to investigate the genetic events associated with ovarian cancer. The frequencies of loss of heterozygosity (LOH) at 16 loci representative of chromosome 3p in 33 tumor biopsies and 47 ovarian primary cultures derived from unselected ovarian cancers were examined. This repertoire also included benign and borderline tumors as well as malignant ovarian ascites. LOH was observed in 25 (31%) samples for at least one marker: 21 of 58 malignant, two of 12 borderline and two of 10 benign specimens. Chromosome 3p loss was not restricted to ovarian tumors of high grade and stage. LOH was observed in both cultured and non cultured tumors and ascites. A spontaneously immortalized cell line derived from a malignant ovarian ascites, OV-90, displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p. The pattern of deletion displayed by these 25 samples enabled the determination of at least two distinct regions of overlapping deletions on chromosome 3p extending from D3S1270 to D3S1597 and from D3S1293 to D3S1283. In addition, a region proximal to D3S1300 was deleted in a subset of samples. Although loss of loci overlapping these three regions (Regions I, II and III) were observed in malignant and benign tumors, in borderline tumors loss was observed of markers representative of Region III only. While RARbeta is presently included in Region II, the minimal regions of deletion exclude VHL, TGFBR2, PTPase(gamma) and FHIT as candidate tumor suppressors in ovarian tumorigenesis.

Entities:  

Mesh:

Year:  1998        PMID: 9811467     DOI: 10.1038/sj.onc.1202152

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

2.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Authors:  Emily N Manderson; Anne-Marie Mes-Masson; Jaroslav Novak; Peter D Lee; Diane Provencher; Thomas J Hudson; Patricia N Tonin
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

3.  Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Authors:  Joseph Kwong; Ji-Young Lee; Kwong-Kwok Wong; Xiaofeng Zhou; David T W Wong; Kwok-Wai Lo; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

4.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

5.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

6.  Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Authors:  Ashley H Birch; Suzanna L Arcand; Kathleen K Oros; Kurosh Rahimi; A Kevin Watters; Diane Provencher; Celia M Greenwood; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

7.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Authors:  Aaron G Lewis; James Flanagan; Anna Marsh; Gulietta M Pupo; Graham Mann; Amanda B Spurdle; Geoffrey J Lindeman; Jane E Visvader; Melissa A Brown; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2005-10-21       Impact factor: 6.466

8.  Impaired FHIT expression characterizes serous ovarian carcinoma.

Authors:  K Ozaki; T Enomoto; K Yoshino; M Fujita; G S Buzard; K Kawano; M Yamasaki; Y Murata
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

9.  Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Authors:  Corine M Beaufort; Jean C A Helmijr; Anna M Piskorz; Marlous Hoogstraat; Kirsten Ruigrok-Ritstier; Nicolle Besselink; Muhammed Murtaza; Wilfred F J van IJcken; Anouk A J Heine; Marcel Smid; Marco J Koudijs; James D Brenton; Els M J J Berns; Jozien Helleman
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

10.  Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Authors:  Neal Al Cody; Magdalena Zietarska; Ali Filali-Mouhim; Diane M Provencher; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  BMC Med Genomics       Date:  2008-08-07       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.